Showing articles whose micro-themes are very close to:
#Opdualag reimbursement
- No closely related articles found yet.
- NCPE Ireland HTA for Opdualag (nivolumab+relatlimab) for advanced melanoma: status update (ncpe.ie) | 18d ago
- NCPE Recommends Belzutifan (Welireg) Not Reimbursed for VHL Disease on Cost-Effectiveness Grounds (ncpe.ie) | 39d ago
- HSE requests HIQA cost-benefit assessment on CGM reimbursement for insulin-dependent type 2 diabetes (imt.ie) | 10d ago
- NCPE Recommends Against Reimbursement of Belzutifan (Welireg) for von Hippel-Lindau Disease in Ireland (ncpe.ie) | 15d ago
Showing page 1 of 1
(4 total results)
← Prev
Next →